Profile data is unavailable for this security.
About the company
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.
- Revenue in USD (TTM)617.51m
- Net income in USD137.70m
- Incorporated2017
- Employees246.00
- LocationHarmony Biosciences Holdings Inc630 W Germantown Pike, Suite 215PLYMOUTH MEETING 19462United StatesUSA
- Phone+1 (484) 539-9800
- Fax+1 (302) 655-5049
- Websitehttps://www.harmonybiosciences.com/
Mergers & acquisitions
Acquired company | HRMY:NMQ since announced | Transaction value |
---|---|---|
Zynerba Pharmaceuticals Inc | -1.07% | 199.65m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Supernus Pharmaceuticals Inc | 607.52m | 1.32m | 1.69bn | 652.00 | 1,216.17 | 1.83 | 19.57 | 2.78 | -0.0152 | -0.0152 | 10.71 | 16.84 | 0.4077 | 0.9918 | 3.92 | 931,780.70 | 0.0883 | 4.95 | 0.1315 | 6.41 | 86.21 | 88.61 | 0.2166 | 12.84 | 1.43 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
Catalyst Pharmaceuticals Inc | 398.20m | 71.41m | 1.74bn | 167.00 | 24.16 | 4.07 | 16.66 | 4.36 | 0.6092 | 0.6092 | 3.56 | 3.62 | 0.9417 | 4.63 | 12.45 | 2,384,455.00 | 16.89 | 25.42 | 20.06 | 29.81 | 86.95 | 85.63 | 17.93 | 30.87 | 2.68 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
Myriad Genetics, Inc. | 753.20m | -263.30m | 1.76bn | 2.70k | -- | 2.23 | -- | 2.34 | -3.20 | -3.20 | 9.09 | 8.71 | 0.6423 | 11.22 | 6.98 | 278,963.00 | -22.45 | -- | -25.66 | -- | 68.64 | -- | -34.96 | -- | 1.87 | -342.25 | 0.0469 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
Inhibrx Inc | 1.80m | -241.36m | 1.79bn | 166.00 | -- | 37.19 | -- | 991.83 | -5.03 | -5.03 | 0.0382 | 0.9184 | 0.006 | -- | 3.53 | 10,843.37 | -80.07 | -77.06 | -93.12 | -93.91 | -- | -- | -13,318.17 | -1,590.91 | -- | -11.00 | 0.8263 | -- | -17.88 | -26.85 | -66.20 | -- | 26.30 | -- |
Harmony Biosciences Holdings Inc | 617.51m | 137.70m | 1.79bn | 246.00 | 13.63 | 3.48 | 11.06 | 2.90 | 2.32 | 2.32 | 10.39 | 9.08 | 0.7906 | 25.72 | 9.34 | 2,510,207.00 | 17.63 | 7.46 | 20.83 | 9.08 | 79.28 | 80.58 | 22.30 | 10.46 | 3.07 | 31.38 | 0.2694 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
Avadel Pharmaceuticals PLC (ADR) | 27.96m | -160.28m | 1.81bn | 154.00 | -- | 19.28 | -- | 64.69 | -2.04 | -2.04 | 0.3491 | 0.9768 | 0.188 | -- | 4.52 | 181,577.90 | -107.75 | -40.21 | -156.49 | -47.99 | 96.97 | -- | -573.17 | -374.75 | 3.36 | -13.94 | 0.00 | -- | -- | -22.99 | -16.59 | -- | -- | -- |
Fusion Pharmaceuticals Inc | 2.07m | -94.90m | 1.82bn | 113.00 | -- | 7.68 | -- | 881.29 | -1.47 | -1.47 | 0.0315 | 2.79 | 0.0082 | -- | 60.82 | 18,300.88 | -37.59 | -35.45 | -40.07 | -38.55 | -- | -- | -4,588.83 | -7,206.24 | -- | -- | 0.1352 | -- | 41.55 | -- | -8.32 | -- | 28.21 | -- |
Edgewise Therapeutics Inc | 0.00 | -100.16m | 1.82bn | 88.00 | -- | 4.31 | -- | -- | -1.57 | -1.57 | 0.00 | 4.53 | 0.00 | -- | -- | 0.00 | -28.33 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.08 | -- | -- | -- |
Structure Therapeutics Inc (ADR) | 0.00 | -89.62m | 1.83bn | 93.00 | -- | 4.03 | -- | -- | -2.51 | -2.51 | 0.00 | 9.76 | 0.00 | -- | -- | 0.00 | -30.91 | -- | -33.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
Syndax Pharmaceuticals Inc | 0.00 | -209.36m | 1.87bn | 112.00 | -- | 3.38 | -- | -- | -2.96 | -2.96 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -37.72 | -27.90 | -40.93 | -30.15 | -- | -- | -- | -324.34 | -- | -- | 0.00004 | -- | -- | -- | -40.19 | -- | -- | -- |
Beam Therapeutics Inc | 377.71m | -132.53m | 1.90bn | 436.00 | -- | 1.92 | -- | 5.04 | -1.87 | -1.87 | 4.90 | 12.02 | 0.2697 | -- | -- | 866,305.10 | -9.46 | -24.54 | -11.17 | -29.26 | -- | -- | -35.09 | -211.96 | -- | -- | 0.0005 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
Ginkgo Bioworks Holdings Inc | 251.46m | -892.87m | 1.94bn | 1.22k | -- | 1.74 | -- | 7.72 | -0.459 | -0.459 | 0.1293 | 0.5482 | 0.1196 | 24.49 | 5.01 | 206,449.10 | -42.47 | -- | -46.17 | -- | 78.52 | -- | -355.08 | -- | 6.11 | -1,703.31 | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.28m | 9.30% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 5.14m | 9.06% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 3.58m | 6.31% |
HBM Partners AG (Investment Management)as of 31 Dec 2023 | 2.15m | 3.78% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.36m | 2.40% |
Pacer Advisors, Inc.as of 31 Dec 2023 | 1.22m | 2.16% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 881.82k | 1.55% |
Camber Capital Management LPas of 31 Dec 2023 | 750.00k | 1.32% |
Geode Capital Management LLCas of 31 Dec 2023 | 738.91k | 1.30% |
Dimensional Fund Advisors LPas of 31 Dec 2023 | 736.27k | 1.30% |